Overview

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the tolerated dose of the combination of decitabine and midostaurin as induction (first cycle of chemotherapy) and consolidation (additional chemotherapy once a patient goes into remission) in people greater than 60 years with newly diagnosed AML or adult patients with relapsed/refractory disease.

Phase:

Phase 1

Details

Lead Sponsor:

University of Kansas

Collaborator:

Novartis

Treatments:

4'-N-benzoylstaurosporine
Azacitidine
Decitabine
Midostaurin
Staurosporine